PCV14 may be administered to infants aged 6, 10 and 14 weeks in three doses
BE's PCV14 will help prevent invasive pneumococcal infection and save millions of lives worldwide. Representational Image/AFP
HYDERABAD: Pharma major Biological E. Limited (BE) on Friday said that its 14-valent paediatric pneumococcal conjugate vaccine (PCV14) against S. pneumoniae infection had received approval from the Drugs Controller General of India (DCGI) for manufacture and commercial sale in India.
PCV14 may be administered to infants aged 6, 10 and 14 weeks in three doses. BE's PCV14 will help prevent invasive pneumococcal infection and save millions of lives worldwide.
Mahima Datla, managing director of BE, said, "With this endorsement, our country has another essential paediatric vaccine. We will be working with regulators in other countries to make our vaccine available globally."
( Source : Deccan Chronicle. )
Next Story
